Clin2
NCT07011511Likely a fitRecruiting

Testing a new malaria drug in healthy volunteers

Malaria, Falciparum

Part of Infections clinical trials.

This trial tests a new malaria drug (MMV055), alone or with another drug (MMV371), to see if it is safe and how the body processes it. It is for healthy people who want to help find new malaria treatments.

Summary written for real people, not researchers, by Clin2.

Phase
Phase 1
Enrollment
72 people
Ages
18 years to 60 years
Study type
Interventional

Who can take part

  • You are between 18 and 60 years old.
  • You are in good health, as determined by medical exams and blood tests.
  • You have a body mass index (BMI) between 19 and 30, and weigh at least 45 kg (women) or 50 kg (men).
  • You must agree to use reliable birth control during the study.
  • You do not have any serious heart, liver, kidney, or lung conditions.
  • You have not taken other investigational drugs in the last 90 days.
  • You do not smoke or use nicotine products (like e-cigarettes) and haven't for the past 12 months.

View the official record on ClinicalTrials.gov

Quick eligibility check

Answer a few plain-language questions, based on this study's own requirements, to get a preliminary sense of fit.

Similar studies

Other trials that look related to this one.

NCT07548021Not yet recruiting· Phase 1
Safety study of MMV371 injection for malaria prevention

This study tests a new long-acting malaria prevention injection (MMV371) in healthy adults and adolescents in Rwanda. Researchers will monitor how safe it is and how your body processes it over 24 weeks.

Kigali
NCT06881732Not yet recruiting· Phase 1
Testing a new malaria vaccine by mosquito bite

This trial uses a genetically modified malaria parasite given by mosquito bite to safely test a new vaccine approach in healthy volunteers. If you qualify, you'll help researchers understand how the body defends against malaria.

Melbourne, Victoria
NCT07545681Not yet recruiting· Phase 2
Testing a new malaria treatment for uncomplicated P. falciparum

This study tests a new experimental antimalarial drug (GSK3772701) to see if it can safely and effectively treat uncomplicated malaria caused by P. falciparum parasites. You would receive the study drug by mouth and be monitored closely with blood tests and heart rhythm checks.

NCT07646353Not yet recruiting· Phase 1
Safety study of GSK4425689A in healthy adults

This is an early-stage safety study testing a new experimental drug (GSK4425689A) in healthy volunteers. Researchers want to find safe doses and understand how the body processes this medication.

NCT06958198Recruiting· Phase 1
Testing a new multi-stage malaria vaccine in adults and children

This trial tests a new combination of experimental malaria vaccines to see if they are safe and help protect against malaria. It includes both adults and young children in malaria-affected areas.

Siglé, Boulkiemdé Province
NCT06862453Recruiting· Phase 1
Safety of a new malaria vaccine in healthy adults

This study tests a new malaria vaccine in healthy adults. You will receive the vaccine and then be exposed to the malaria parasite in a controlled setting to check if the vaccine protects you.

Tübingen

Hear when a new Malaria Falciparum trial opens

We’ll email you when one opens — at most once a week, no account needed, unsubscribe anytime.